




























hCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 4 (2013) 976– 980
Contents lists available at ScienceDirect
International  Journal  of  Surgery  Case  Reports
journa l h om epage: www.caserepor ts .com
ong-term  survival  after  sequential  chemotherapy  and  surgery
or  advanced  gastric  cancer
akashi  Orii ∗, Yukihiko  Karasawa,  Hiroe  Kitahara,  Masaki  Yoshimura,  Motohiro  Okumura
epartment of Gastroenterological Surgery, Showa Inan General Hospital, 3230 Akaho, Komagane, Nagano 399-4117, Japan
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 20 July 2013
eceived  in revised form 24 July 2013
ccepted 25 July 2013
eywords:
astric cancer
ortal  vein tumor thrombus
iver  metastasis
eritoneal dissemination
a  b  s  t  r  a  c  t
INTRODUCTION:  We  experienced  a case  with  long  relapse-free  survival  after  successful  treatment  of
chemotherapy  and  surgery  to  advanced  gastric  cancer.
PRESENTATION OF  CASE: A  56-year-old  man  was  examined  because  of  rapid  weight  loss and  was  diagnosed
as  having  far-advanced  gastric  cancer  with  portal  vein  tumor  thrombus  (PVTT)  and  liver, lymph  node  and
peritoneal  metastases.  Immediately  after  beginning  chemotherapy,  gastric  obstruction  due  to  gastric
cancer  was  discovered.  Therefore  gastrojejunostomy,  a bypass  operation,  was  performed,  and  this  was
followed  by  the ﬁrst  course  chemotherapy  with  S-1  and  cisplatin.  After 4 courses  of  this  regimen  were
completed,  PVTT  and  the peritoneal  metastasis  could  no  longer  be conﬁrmed,  and  new  lesion  had  not
appeared;  therefore,  the  patient  underwent  a radical  operation  with  distal  gastrectomy,  lymph  nodeastrojejunostomy dissection  and partial  hepatectomy.  After  the  operation,  he  received  second-line  chemotherapy  with  S-1
and  paclitaxel  for  1  year.  He has  been  in  good  health  without  any  signs  of  recurrence  for  3  years  and  8
months  after  the radical  operation.
DISCUSSION AND  CONCLUSION:  Although  complete  recovery  from  far-advanced  gastric  cancer  is rarely





Gastric cancer with portal vein thrombosis is relative rare. How-
ver, this malignancy has a poor prognosis, and long-term survival
s often not expected in cases with peritoneal metastases.
Herein, we describe the case of a patient who  was clini-
ally cancer free for a long period after chemotherapy. Prior to
hemotherapy, the patient had undergone a bypass operation, and
hemotherapy was followed by radical gastrectomy and partial
epatectomy.
. Presentation of caseA 56-year-old man  visited his family physician with complaints
f dizziness and rapid weight loss. A palpable mass was  detected
n his upper abdomen, and severe anemia was conﬁrmed by blood
ests. Therefore, he was referred to the gastroenterological depart-
ent of our hospital.
∗ Corresponding author. Tel.: +81 265 82 2121; fax: +81 265 82 2317.
E-mail  address: t.orii@sihp.jp (T. Orii).
210-2612 ©
 
 2013 The Authors. Published by Elsevier Ltd on behalf of Surgical Associate
ttp://dx.doi.org/10.1016/j.ijscr.2013.07.031he Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. 
Upper gastrointestinal endoscopy revealed a large type 3 tumor
in the gastric antrum, expanding to the duodenal bulb (Fig. 1a).
Biopsy of the tumor resulted in a diagnosis of well-differentiated
adenocarcinoma.
Computed tomography (CT) showed a thickening of the entire
gastric wall from the antrum to the pylorus (Fig. 1b), with multiple
lymph node metastases. In addition, a tumor thrombus progressing
to the superior mesenteric vein through the gastroepiploic vein
was observed (Fig. 2a). In addition, a liver tumor, 15 mm in size,
was noted (Fig. 3). Peritoneal disseminated metastasis was also sus-
pected because of the presence of ascites in the rectovesicular fossa
and a rise in the concentration of omental adipose tissue (Fig. 4a).
Laboratory  results conﬁrmed severe anemia (red blood cell
count, 3.27 × 106/mm3; hemoglobin level, 6.4 g/dl; hematocrit,
23%) and the carcinoembryonic antigen level was signiﬁcantly high
at 770 ng/dl. Liver and renal function test results were within nor-
mal  limits, and no abnormal ﬁndings were observed.
On the basis of these ﬁndings, the patient was diagnosed as
having far-advanced, unresectable gastric cancer. Therefore, we
started a chemotherapy regimen of S-1 (120 mg/body) and cisplatin
(60 mg/m2) 2 weeks after his ﬁrst visit to our hospital.
Open access under CC BY-NC-ND license.During  the ﬁrst course of the chemotherapy, the patient com-
plained of frequent nausea and vomiting. Abdominal radiography
showed severe dilatation of the proximal stomach, conﬁrming that
stenosis of the stomach was the cause of his complaints. Five weeks
after beginning chemotherapy, gastrojejunostomy (a bypass opera-
tion) was  performed to improve and maintain nutritional status and
s Ltd. Open access under CC BY-NC-ND license. 
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Fig. 1. Gastric cancer before anticancer treatment. (a) Findings of upper gastrointestinal endoscopy. The antrum of the stomach is occupied by Bormann 3-type cancer. (b)
Computed tomography of the coronal section shows remarkable thickening of the wall at the distal half of the stomach.
Fig. 2. Change in the tumor thrombus in the portal vein after chemotherapy. (a) Computed tomography at the ﬁrst visit to our hospital. The black arrow indicates the tumor
thrombus in the superior mesenteric vein. (b) After 4 courses of chemotherapy, the tumor thrombus disappeared completely (the black arrow head).
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Fig. 4. Change in the peritoneal disseminated metastases around the greater omen-
tum. (a) Before chemotherapeutic treatment, many nodules of various sizes and an
increase in the concentration of adipose tissue were observed. (b) After treatment,
many nodules had almost disappeared.ig. 3. The solitary metastatic tumor of the liver (the black arrow) did not change,
espite the administration of chemotherapy before the radical operation.
acilitate continuation of anticancer chemotherapy. Chemotherapy
as resumed 2 weeks after the operation, and therapy could be
dministered as scheduled.
After completing 4 courses of the chemotherapy regimen,
lanned CT examination showed that the tumor thrombus of
he portal venous system (Fig. 2b) and disseminated peritoneal
etastases had disappeared (Fig. 4b). In addition, the number
f liver metastases had not increased and stable disease was
chieved in the gastric lesions and metastatic lymph nodes. The
adical resection was considered possible, and this was performed
 months after the beginning of chemotherapy. Peritoneal dissem-
nated metastases, conﬁrmed during the ﬁrst operation, were not
onﬁrmed macroscopically, and cancer cells were not detected
n a cytological specimen from peritoneal lavage. On the basis
f the above ﬁndings, we performed radical surgery, i.e., distal
astrectomy (Fig. 5) (Billroth II reconstruction) with regional
ymph node dissection and partial hepatectomy. Five weeks after
he operation, the second regimen of chemotherapy with S-1
120 mg/body) and paclitaxel (50 mg/m2) was administered in 14
Fig. 5. Macroscopic ﬁndings of the resected stomach. Type 3 cancer involving the entire circumference of the stomach was conﬁrmed.































































T. Orii et al. / International Journal 
ourses over a period of 1 year. The patient has been followed-up
n a regular basis at our hospital, and there have been no signs of
ecurrence 4.5 years after radical surgery.
. Discussion
Portal vein tumor thrombus (PVTT) originating from gastric
ancer is a rare condition. According to the Annual Report of the
athological autopsy cases in Japan (vol. 40, 1998), the incidence
f portal vein metastasis in gastric cancer was  1.2% (29/2330).1
akayasu et al. also reported only 1 case of gastric cancer combined
ith PVTT in 3176 cases of gastric resection.2
The prognosis of gastric cancer patients who develop PVTT is
oor. The median survival of gastric cancer patients with PVTT is
.4 months, and the 5-year survival rate is less than 10%.3 Sugawara
t al. analyzed the clinical data of 11 cases reported in the literature,
ith or without liver metastasis.4 Of 6 patients with liver metasta-
is, 5 died, and the longest survival time was 7 months. Five of the 11
atients did not have associated liver metastasis. Surgical resection
as performed in 4 of these 5 patients: 3 patients were alive for 2
onths, 14 months, and 24 months postoperatively. The remaining
atient died 21 months after surgery. Although patients with PVTT
ut without liver metastasis seem likely to achieve long-term prog-
osis, the precise prognostic superiority of patients without liver
etastasis is difﬁcult to determine. PVTT is considered to be an
arly step in liver metastasis because metastasis is established
hen cancer cells released from the primary focus enter the portal
loodstream and are transported to the liver.
The standard therapeutic regimen for advanced unresectable
astric cancer in Japan is described in the Japanese gastric cancer
reatment guidelines.5 Based on results from the SPIRIT trial6
nd the JCOG 9912 trial,7 the combination of S-1 and cisplatin is
ecommended as the ﬁrst-line regimen in the guideline. Although
he complete response plus partial response rate is 54%, the
edian and progression-free survival times are only 13.0 months
nd 6.0 months, respectively. Therefore, the effectiveness of this
egimen has not been satisfactory. Recently, the effectiveness of
ombination therapy with trastuzumab to treat human epidermal
rowth factor receptor type 2 (Her2)-positive advanced gastric
ancer was reported in the ToGA trial,8 and this regimen of
apecitabine, cisplatin, and trastuzumab is recommended in the
apanese guidelines.
Previous case studies have reported on the effectiveness of
hemotherapy for PVTT originating from gastric cancer; however,
he regimens used differ across studies and the basis for the use of
hese regimens has not been described.9–11 Accordingly, their use
oes not seem to be justiﬁed.
Peritoneal metastasis originating from gastric cancer is a dis-
ase with a very poor prognosis, and treatment is difﬁcult in almost
ll cases. Many reports on the effectiveness of paclitaxel for perit-
neal metastasis have recently been published, and combination
reatment with S-1 was administered in almost all cases.12,13 Fur-
hermore, the validity of intraperitoneal paclitaxel injection, in
ddition to systemic administration, was reported.14 The efﬁcacy
nd tolerability of combined intravenous and intraperitoneal pacli-
axel injection and oral administration of S-1 were also proved in
nother phase 2 study.15
As described in the Japanese guidelines,5 S-1 is a key drug for
astric cancer; however, since it is administered orally, it cannot
e used in cases of gastrointestinal stenosis. In our case, in order to
ontinue oral administration of S-1, gastrojejunostomy was per-
ormed as soon as possible upon appearance of gastric pyloric
tenosis. Bypass operations, such as gastrojejunostomy,16,17 should
e performed in order to not only continue optimal chemotherapy,
ut also to maintain a satisfactory nutritional status.
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4. Conclusion
We encountered a case of successful, consecutive anticancer
treatment for far-advanced gastric cancer with PVTT and liver and
peritoneal metastases. Treatment included a gastrojejunal bypass
operation, chemotherapy, and a radical operation, followed by
adjuvant chemotherapy for 1 year. Although complete recovery
from this malignancy is rarely expected, this case demonstrates
that long-term survival is achievable with carefully considered
treatment plans.





Written informed consent was obtained from the patient for
publication of this case report and case series and accompanying
images. A copy of the written consent is available for review by the
Editor-in-Chief of this journal on request.
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